Recombinant Vaccines for Prevention of AIDS and Other Diseases
$805,377ZIAFY2009AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Linked publications & trials
Paper 38536937Paper 34232734Paper 33688035Paper 33442693Paper 32019881Paper 31145755Paper 30778066Paper 30541829Paper 29869530Paper 29669026Paper 29257056Paper 29237847Paper 29021394Paper 28968759Paper 28721397Paper 28588133Paper 28060405Paper 28027665Paper 27683750Paper 27466414Paper 27006959Paper 26528782Paper 26528781Paper 26116502Paper 25875843Paper 25874723Paper 25653428Paper 24920805Paper 24403557Paper 24243013Paper 23928462Paper 23677609Paper 23583893Paper 23390298Paper 23049876Paper 23035853Paper 22234262Paper 22178526Paper 21864626Paper 21628671Paper 21377510Paper 21282192Paper 21085591Paper 21076059Paper 19995539Paper 19654066Paper 19450644Paper 19420086Paper 19224993Paper 19135115Paper 18808335Paper 18793787Paper 18160013Paper 17579577Paper 17360078Paper 17201662Paper 16725169Paper 16472543Paper 16409123Paper 16267024Paper 16083934Paper 16023165Paper 15780866Paper 15731219Paper 15725752Paper 15650426Paper 15380355Paper 15367588Paper 15315833Paper 15249657Paper 15242543Paper 15242542Paper 15161069Paper 15096611Paper 15070762Paper 15014500Paper 14963123Paper 12970455Paper 12869693Paper 12477888Paper 12097599Paper 11983252Paper 11752436Paper 11393868Paper 10775580Paper 10684290
Abstract
There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this information to develop candidate vaccines. Live recombinant viral vaccines, DNA vaccines and recombinant protein vaccines are being developed. The vaccines are first tested in small animals and then in non-human primates. Presently we are working on vaccines for HIV.
View original record on NIH RePORTER →